Answers are grounded in this paper and cite their sources.
The size and scope of the impacts of HPV vaccines to date are somewhat extraordinary, given their apparent limitations and the public health challenges faced at the outset in attempting to implement mass HPV immunisation programs. These limitations and challenges included the vaccine's type specificity, need to be given prior to exposure, the three-dose schedule, target age group of early adolescence, and potential communication challenges around HPV being a sexually transmitted infection (STI). Added to this there is considerable complexity and cost in the design, conduct and interpretation of infection and disease surveillance studies following implementation of an HPV vaccine program [1]. In recognition of this, WHO does not consider that the ability to undertake post vaccination impact surveillance is a prerequisite for implementing a program [2]. However there is an undoubtedly high level of interest in being able to assess the health benefits of this anti-cancer intervention such that these is now an abundance of evidence from multiple countries, with a range of coverage and implementation strategies, that shows the vaccines are effective in real world use.
No takes yet. Share an insight, caveat, or question.
Julia Brotherton (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: